Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial

• Published in: Medical oncology (Northwood, London, England) Vol. 38; no. 9; p. 108
• Main Authors: Ghonaim, Eman, El-Haggar, Sahar, Gohar, Suzy
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2021; Springer Nature B.V
• Subjects: Acute Kidney Injury - chemically induced; Acute Kidney Injury - drug therapy; Acute Kidney Injury - pathology; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biomarkers; Chemotherapy; Cisplatin - administration & dosage; Creatinine; Docetaxel - administration & dosage; Female; Fluorouracil - administration & dosage; Follow-Up Studies; Head & neck cancer; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - pathology; Hematology; Humans; Internal Medicine; Kidneys; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Paper; Pantoprazole - therapeutic use; Pathology; Prognosis; Proton Pump Inhibitors - therapeutic use; Retrospective Studies; NGAL; KIM-1; Soluble FasL; Pantoprazole; Cisplatin
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-021-01558-y

Cisplatin is used to treat solid malignancies including head and neck cancer. However, nephrotoxicity limits its use. In this study, we looked for a possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity. We used novel biomarkers for early detection of nephrotoxicity. Sixty chemotherapy naïve head and neck cancer patients completed the study. Following complete history taking and thorough clinical examination, patients were randomly divided into three groups: 20 patients in each. Group I (control group) received cisplatin without pantoprazole, groups II and III received pantoprazole 80 mg and 40 mg, respectively, concurrently with cisplatin. Blood and urine samples were collected at baseline, and 48 h after the first and third cycles of cisplatin administration. Assessment of serum creatinine and soluble FasL (sFasL), as well as urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) was performed. Nephrotoxicity was detected in 6 patients in group I, none in group II and 3 patients in group III. Serum creatinine significantly increased at the end of treatment in group I compared to groups II and III. Group I also had significantly higher urinary KIM-1 and NGAL and serum sFasL compared to groups II and III after the first and third cycles. On the contrary, there was no significant difference between groups II and III. Pantoprazole prevented the increase in acute kidney injury biomarkers in cisplatin-treated patients. Therefore, it is a promising agent in reducing cisplatin-induced nephrotoxicity. Trial registration Clinical Trials.gov identifier:  NCT04217512 , registered in January 2020 " retrospectively registered".